1. Tsujimoto T, Kajio H, Sugiyama T. Obesity, diabetes, and length of time in the United States: Analysis of National Health and Nutrition Examination Survey 1999 to 2012. Medicine (Baltimore). 2016; 95:e4578. PMID:
27583867.
2. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004; 4:579–591. PMID:
15286738.
Article
3. Byers T, Sedjo RL. Body fatness as a cause of cancer: epidemiologic clues to biologic mechanisms. Endocr Relat Cancer. 2015; 22:R125–R134. PMID:
25870250.
Article
4. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013; 63:800–809. PMID:
23219374.
Article
5. Parikesit D, Mochtar CA, Umbas R, Hamid AR. The impact of obesity towards prostate diseases. Prostate Int. 2016; 4:1–6. PMID:
27014656.
Article
6. Golabek T, Bukowczan J, Chłosta P, Powroźnik J, Dobruch J, Borówka A. Obesity and prostate cancer incidence and mortality: a systematic review of prospective cohort studies. Urol Int. 2014; 92:7–14. PMID:
23942223.
Article
7. Mistry T, Digby JE, Desai KM, Randeva HS. Obesity and prostate cancer: a role for adipokines. Eur Urol. 2007; 52:46–53. PMID:
17399889.
Article
8. McGown C, Birerdinc A, Younossi ZM. Adipose tissue as an endocrine organ. Clin Liver Dis. 2014; 18:41–58. PMID:
24274864.
Article
9. Baillargeon J, Rose DP. Obesity, adipokines, and prostate cancer (review). Int J Oncol. 2006; 28:737–745. PMID:
16465380.
Article
10. Kim MK, Lee WY, Kang JH, Kang JH, Kim BT, Kim SM, et al. 2014 clinical practice guidelines for overweight and obesity in Korea. Endocrinol Metab (Seoul). 2014; 29:405–409. PMID:
25559568.
Article
11. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371:569–578. PMID:
18280327.
Article
12. Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer: a doseresponse meta-analysis of prospective studies. Ann Oncol. 2012; 23:1665–1671. PMID:
22228452.
13. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2011; 4:486–501. PMID:
21233290.
Article
14. de Cobelli O, Terracciano D, Tagliabue E, Raimondi S, Galasso G, Cioffi A, et al. Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance. Urol Oncol. 2015; 33:201.e1–201.e8.
Article
15. Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med. 2010; 61:301–316. PMID:
19824817.
Article
16. Alshaker H, Sacco K, Alfraidi A, Muhammad A, Winkler M, Pchejetski D. Leptin signalling, obesity and prostate cancer: molecular and clinical perspective on the old dilemma. Oncotarget. 2015; 6:35556–35563. PMID:
26376613.
Article
17. Onuma M, Bub JD, Rummel TL, Iwamoto Y. Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem. 2003; 278:42660–42667. PMID:
12902351.
18. Somasundar P, Frankenberry KA, Skinner H, Vedula G, McFadden DW, Riggs D, et al. Prostate cancer cell proliferation is influenced by leptin. J Surg Res. 2004; 118:71–82. PMID:
15093720.
19. Frankenberry KA, Somasundar P, McFadden DW, Vona-Davis LC. Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am J Surg. 2004; 188:560–565. PMID:
15546570.
Article